Related Experiment Video
Updated: Mar 8, 2026
Multiplex PCR Assay for Typing of Staphylococcal Cassette Chromosome Mec Types I to V in Methicillin-resistant Staphylococcus aureus
Published on: September 5, 2013
Nasal Methicillin-Resistant Staphylococcus aureus (MRSA) PCR Testing Reduces the Duration of MRSA-Targeted Therapy in
Nidhu Baby1,2, Andrew C Faust3, Terri Smith1
1Texas Health Resources Presbyterian Hospital of Dallas, Department of Pharmacy, Dallas, Texas, USA.
Abstract:
The objective of this study was to evaluate the impact of pharmacist-ordered methicillin-resistant Staphylococcus aureus (MRSA) PCR testing on the duration of empirical MRSA-targeted antibiotic therapy in patients with suspected pneumonia. This is a retrospective analysis of patients who received vancomycin or linezolid for suspected pneumonia before and after the implementation of a pharmacist-driven protocol for nasal MRSA PCR testing. Patients were included if they were adults of >18 years of age and initiated on vancomycin or linezolid for suspected MRSA pneumonia. The primary endpoint was the duration of vancomycin or linezolid therapy. After screening 368 patients, 57 patients met inclusion criteria (27 pre-PCR and 30 post-PCR). Baseline characteristics were similar between the two groups, with the majority of patients classified as having health care-associated pneumonia (68.4%). The use of the nasal MRSA PCR test reduced the mean duration of MRSA-targeted therapy by 46.6 h (74.0 ± 48.9 h versus 27.4 ± 18.7 h; 95% confidence interval [CI], 27.3 to 65.8 h; P < 0.0001). Fewer patients in the post-PCR group required vancomycin serum levels and dose adjustment (48.1% versus 16.7%; P = 0.02). There were no significant differences between the pre- and post-PCR groups regarding days to clinical improvement (1.78 ± 2.52 versus 2.27 ± 3.34; P = 0.54), length of hospital stay (11.04 ± 9.5 versus 8.2 ± 7.8; P = 0.22), or hospital mortality (14.8% versus 6.7%; P = 0.41). The use of nasal MRSA PCR testing in patients with suspected MRSA pneumonia reduced the duration of empirical MRSA-targeted therapy by approximately 2 days without increasing adverse clinical outcomes.
Insights
Pharmacist-ordered methicillin-resistant Staphylococcus aureus (MRSA) PCR testing significantly reduced antibiotic duration for suspected pneumonia. This targeted approach shortened therapy by nearly two days without impacting patient outcomes.
Area of Science:
- Infectious Diseases
- Clinical Pharmacy
- Diagnostic Microbiology
Background:
- Empirical antibiotic therapy for suspected methicillin-resistant Staphylococcus aureus (MRSA) pneumonia often leads to prolonged treatment durations.
- Optimizing antibiotic use is crucial to reduce patient exposure and healthcare costs.
Purpose of the Study:
- To evaluate the impact of pharmacist-ordered nasal MRSA PCR testing on the duration of empirical MRSA-targeted antibiotic therapy in pneumonia patients.
- To assess if implementing a pharmacist-driven protocol for MRSA PCR testing influences antibiotic treatment duration and clinical outcomes.
Main Methods:
- Retrospective analysis of adult patients treated with vancomycin or linezolid for suspected MRSA pneumonia.
- Comparison of outcomes before and after the implementation of a pharmacist-driven nasal MRSA PCR testing protocol.
- Primary endpoint: duration of MRSA-targeted antibiotic therapy.
Main Results:
- The nasal MRSA PCR test significantly reduced the mean duration of MRSA-targeted therapy by 46.6 hours (74.0 vs. 27.4 hours; P < 0.0001).
- Fewer patients in the post-PCR group required vancomycin serum level monitoring and dose adjustments (16.7% vs. 48.1%; P = 0.02).
- No significant differences were observed in clinical improvement, length of hospital stay, or mortality between the groups.
Conclusions:
- Pharmacist-ordered nasal MRSA PCR testing effectively reduces the duration of empirical MRSA-targeted antibiotic therapy in suspected pneumonia cases.
- This diagnostic strategy shortens antibiotic exposure by approximately two days without compromising patient safety or clinical outcomes.
